The sphingolipid ceramide is an important second signal molecule that regulates diverse signaling pathways involving apoptosis, cell senescence, the cell cycle, and differentiation. For the most part, ceramide's effects are antagonistic to growth and survival. Interestingly, ceramide and the pro-growth agonist, diacylglycerol (DAG) appear to be regulated simultaneously but in opposite directions in the sphingomyelin cycle. While ceramide stimulates signal transduction pathways that are associated with cell death or at least are inhibitory to cell growth (eg stress-activated protein kinase, SAPK, pathways), DAG activates the classical and novel isoforms of the protein kinase C (PKC) family. These PKC isoforms are associated with cell growth and cell survival. 
Introduction
Ceramide is a naturally occurring sphingolipid that is a key component in the sphingomyelin cycle. 1 In this capacity, ceramide serves an important role in membrane structure. During growth conditions, ceramide and phosphatidylcholine are converted to sphingomyelin by sphingomyelin synthase. 1 A byproduct of this reaction is diacylglycerol (DAG), a potent protein kinase C (PKC) activator. 2 Since DAG-mediated PKC signaling pathways tend to support cell survival, 3, 4 system exists whereby membrane building blocks and growth agonists are produced during conditions favorable to cell growth. In contrast, stress stimuli promote the breakdown of sphingomyelin by phospholipases known as sphingomyelinases (SMase) and ceramide is produced. Like DAG, ceramide has emerged as an important second messenger molecule, except that ceramide-mediated signaling usually involves stress pathways. [5] [6] [7] [8] [9] [10] [11] Since at least one enzyme (sphingomyelin synthase) appears to regulate DAG and ceramide simultaneously but in opposite directions, it is possible that DAG and ceramide have counterbalancing effects on cell growth and apoptosis. 12 Consistent with the notion that DAG and ceramide have counterbalancing effects, DAG can attenuate the effects of ceramide 13 and ceramide can antagonize DAG by inhibiting PKC. [14] [15] [16] An elegant homeostatic regulatory system is emerging with DAG as a growth positive regulator and ceramide as a negative growth regulator. Since each effector is able to transmodulate the signaling pathways regulated by the other, it is possible that net expression of DAG vs ceramide may create a sort of cellular rheostat. 13 It is possible that the dominant second signal molecule produced during growth (ie DAG) or stress (ie ceramide) conditions could promote signal pathways that determine post-translational modification of potential 'survival sensor' molecules (eg Bcl2 17 ). Ceramide is produced during diverse stress stimuli including chemotherapeutic drug treatment, [18] [19] [20] TNF ␣ treatment, 21 ischemia/reperfusion, 22 FAS antigen activation, 23 corticosteroid treatment, 24 or irradiation. 24 The generation of ceramide is so common during apoptosis that it has been considered a universal feature of this process. 1, 3 It is becoming increasingly clear that ceramide is a key regulator of stress signaling pathways involved in apoptosis signaling, cell cycle control, cellular senescence, and cell differentiation. [5] [6] [7] [8] [9] [10] [11] Ceramide activates a number of kinases ( Figure 1 ) including stress-activated protein kinases (SAPKs) such as the jun kinases (JNKs [25] [26] [27] ), kinase suppressor of Ras (KSR [28] [29] [30] , and the atypical PKC isoform, PKC . [31] [32] [33] Conversely, ceramide can inhibit kinases such as the classical and novel PKC isoforms (eg PKC ␣ [14] [15] [16] ) and the PKB kinase, Akt. 29, [34] [35] [36] The mechanism of kinase inhibition appears to involve ceramide's ability to activate protein phosphatases (Figure 1 and Refs 16, 17, [36] [37] [38] [39] . The ceramide-activated protein phosphatase (CAPP) is probably a member(s) of the PP2A family 37, 38 although ceramide can activate PP1 as well. 39 Ceramide activation of protein phosphatases not only suppresses survival signaling pathways by inactivation of kinases, but also directly dephosphorylate substrates directly involved in cell survival (eg Bcl2 17 ). This review will focus on ceramide as a stress second signal molecule and the stress signaling pathway this important sphingolipid regulates including a novel pathway that regulates protein synthesis.
Figure 1
Ceramide activates both protein kinases and protein phosphatases. Ceramide activation of protein kinases (eg JNK, PKC ) and protein phosphatases (eg PP1 and PP2A) allows ceramide to regulate multiple stress signaling pathways. Since a number of different substrates are involved, ceramide is a potent effector molecule.
Ceramide is generated by multiple metabolic pathways
Considerable interest has developed in ceramide metabolism over the past few years. Ceramide is actually a family of highly hydrophobic molecules that contain a variable length fatty acid (containing 2 to 28 carbons) linked to sphingosine or a related long chain base. 40 Ceramide serves multiple physiologic roles. Ceramide is an important intermediate in sphingomyelin biosynthesis. 1 In addition to its role in the metabolism of membrane building blocks (ie sphingomyelin), ceramide's unique physical properties contribute to membrane structure by influencing membrane lipid ordering and by affecting membrane porosity. 41 In fact, ceramide formation with concomitant sphingomyelin hydrolysis appears to be necessary for the changes in membrane morphology (eg blebbing, vasculization, and externalization of phosphatidylserine) that are the hallmark features of the execution phase of apoptosis. 42 In addition to its metabolic and structural roles, it is becoming increasingly clear that ceramide plays a critical role in transmembrane signaling, particularly in response to stress challenges. [5] [6] [7] [8] [9] [10] [11] Therefore, it is not surprising that there are multiple physiologic pathways that produce ceramide.
Ceramide can be generated (1) as a byproduct of sphingomyelin hydrolysis, (2) via de novo pathways involving ceramide synthase, or (3) by the breakdown of complex glycosphingolipids. Cellular generation of ceramide appears to involve some level of topological control since the various metabolic enzymes involved appear to have preferred sub-cellular compartments. 40 The de novo synthesis of ceramide occurs in the endoplasmic reticulum (ER) and in mitochondrial membranes. 19, 40 Ceramide production during sphingomyelin hydrolysis occurs in multiple locations depending on the particular SMase involved. [43] [44] [45] [46] [47] [48] The sphingomyelin pathways have garnered particular attention considering that NiemannPick disease is the result of a deficiency in acidic sphingomyelinase. 49 In addition, the availability of SMase knockout mouse models has enabled investigators to monitor the effect of SMase function on apoptosis. 45, 48 The sphingomyelin pathway for ceramide generation demonstrates the versatility of effector responses that can be generated by ceramide. In fact, divergent responses from a single receptor may be generated depending on whether neutral SMase or acidic SMase is involved. 41 Signaling pathways mediated by the TNF 55 kDa receptor (p55) may result in an inflammatory response or the induction of apoptosis. 41, [50] [51] [52] [53] [54] To trigger the pro-inflammatory cascade, neutral SMase is coupled to p55 via the FAN protein. 52, 54 Activation of apoptosis via the TNF receptor involves activation of acidic SMase through the p55 death domain. 53 There is also evidence that neutral SMases participate in apoptotic mechanisms. [55] [56] [57] For instance, neutral SMase been shown to be involved in hypoxia induced apoptosis in PC12 cells. 57 These findings suggest that the level of regulation of ceramidemediated responses is complex.
Other molecules involved in ceramide biosynthesis regulate ceramide-mediated pathways
The influences of other effectors that oppose or support ceramide-regulated signal pathways also seem to be important in the regulation of the SMase pathway. The effect of DAG, a molecule that antagonizes ceramide's actions and is oppositely regulated from ceramide in the sphingomyelin cycle, is discussed above. Another molecule that can apparently antagonize ceramide-mediated signaling is glutathione. It has recently been discovered that neutral SMase is inhibited by glutathione. 58 Since glutathione depletion is associated with apoptotic stresses such as treatment with peroxide or alkylating agents, 59 depletion of glutathione may be necessary for ceramide production. 58 This potential regulatory loop links oxidative stress pathways with ceramide-mediated signaling. 59 Like DAG, effectors that antagonize ceramide action are sometimes byproducts of ceramide metabolism. Deacylation of ceramide by ceramidases yields sphingosine. A number of ceramidases have been identified in various subcellular locations including lysosomes and membranes. [60] [61] [62] Like ceramide, sphingosine exerts divergent effects depending on cell type. 9 Sphingosine promotes apoptosis in U937 cells 27, 63, 64 and prostate cancer cells, 65 induces cell arrest in Chinese hamster ovary cells, 66 and promotes proliferation of Swiss 3T3 cells. 67 Sphingosine has different effects on stress signaling pathways when compared to ceramide. Ceramide promotes Jun phosphorylation while sphingosine does not. 27 While sphingosine weakly stimulates SAPK pathways and strongly inhibits MAPK pathways, ceramide demonstrates the opposite effect. 27 Sphingosine is rapidly converted to sphingosine-1 phosphate (SPP) upon stimulation of sphingosine kinase by growth receptors like nerve growth factor. 68 SPP promotes extracellular signal receptor kinase (ERK) pathways and mitogenesis. [68] [69] [70] Thus, sphingosine can be converted from a growth antagonist to an effector that promotes growth. Likewise, modifications of ceramide also alter effector activity. Phosphorylation of ceramide results in a molecule that supports growth. 71 Ceramide kinase produces ceramide1-phosphate, a molecule which supports cell growth and promotes DNA synthesis in a manner that is antagonized by ceramide. 72, 73 Another mechanism to modulate ceramide's function biochemically involves glycosylation. Glycosylation of ceramide inactivates the molecule's negative growth effects and thus glycosylation may serve as a mechanism for the cell to tolerate excess ceramide levels. 74 Supporting this notion, an association has been found between multidrug resistance and glycosylceramide levels in breast cancer cell lines.
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Ceramide activates protein kinases that are associated with stress signaling pathways Ceramide-induced apoptosis often involves the SAPK/JNK signaling pathway. 76 In U937 cells, the ability of the TAM-67-dominant negative c-jun mutant to block ceramide-induced apoptosis suggested that ceramide initiated a SAPK cascade that resulted in c-jun phosphorylation. 76 There are three genes that encode JNK (␣, ␤, and ) with 12 possible isoforms derived from alternative splicing products. [77] [78] [79] JNK is activated by diverse stress stimuli, 77 while mitogenic stimuli are poor JNK agonists. 78 In fact, it appears that ceramide redirects cellular signaling pathways by promoting SAPK cascades at the expense of MAPK pathways. 27 In addition to the induction of apoptosis, ceramide activation of SAPK pathways induces cell cycle arrest and inhibits cell proliferation. 33 Thus conditions that favor ceramide generation promote JNK activation. The mechanism by which ceramide activates JNK is not yet clear. Ceramide has been suggested to activate JNK via Rac-1, 80 PKC , 31, 33, 79, 81 and TAK-1. 82 It is also unclear which JNK substrates may participate in ceramide-induced cell death pathways. A number of transcription factors have been suggested as downstream targets for ceramide-activated JNK including AP-1 and GADD153. 8, 80, 83 However, the requirement for the participation of these factors in effectormediated processes may vary by cell type. For instance, AP-1 appears to be required in ceramide-induced apoptosis in human leukemia HL-60 cells and U937 cells. 27, 83, 84 However, c-jun/AP-1 is not essential to sphingosine-induced apoptosis in human leukemia U937 cells. 27, 84 An understanding of the potential effects ceramide-activated JNK may have on cell survival via a transcriptional mechanism(s) will require the identification of the genes whose expression are affected by ceramide-activated JNK. One candidate that has emerged is cyclooxygenase-2 (Cox2 85, 86 ). However, while overexpression of Cox2 has been shown to impede cell cycle progression, 87 Cox2 inhibits apoptosis. 88 Thus downstream JNK targets other than Cox2 are probably involved in apoptotic mechanisms involving ceramide. A potential JNK substrate involved in ceramide-mediated apoptosis is the cellular PKR regulator, RAX. 89 Interestingly, ceramide activation of RAX involves protein translation rather than transcription. This novel ceramide regulatory mechanism will be discussed in greater detail later.
Ceramide activates a number of non-SAPK kinases
Ceramide is known to activate a number of non-SAPK kinases including KSR [28] [29] [30] and PKC . [31] [32] [33] As described earlier, ceramide can mediate either pro-inflammatory or pro-apoptotic processes.
41,50-54 KSR appears to mediate pro-inflammatory responses except when the pro-apoptotic Bcl2 family member, BAD, is present.
9,29 KSR apparently is required in both TNF ␣ and ceramide-induced activation of ERK1/ERK2 in intestinal epithelial cells as evidenced in mouse colon cells expressing kinase-inactive, dominant negative KSR. 90 The mechanism of KSR activation of ERK1/ERK2 involves the activation of Raf-1. 90 Ceramide appears to mediate multiple mechanisms involvLeukemia ing PKC . [31] [32] [33] 91 PKC has been shown to suppress cell growth in human embryonic kidney cells by the activation of SAPK pathways. 33 Expression of constitutive active PKC induced cell cycle arrest while a dominant negative PKC protein blocked SAPK activation by ceramide. 33 PKC may also have a role in inflammatory pathways. While Rac-1 has been implicated in JNK activation by ceramide, 80 PKC stimulation by lipopolysacharide activates JNK by a Rac-independent mechanism involving PI 3 kinase. 91 In addition, PKC has been shown to negatively regulate PKB/Akt. 92 Since PKB/Akt has been identified as a physiologic Bad kinase, 93, 94 it is possible that PKC may regulate ceramide-induced death pathways involving Bad. PP2A has also been implicated in Akt inactivation 35, 36 Thus the regulation of Bad pro-apoptotic function appears to involve both protein phosphatases and protein kinases.
Ceramide activates the protein phosphatases PP2A and PP1
Ceramide is a potent activator of both PP2A 37, 38 and PP1. 39 The mechanism of ceramide activation of these protein phosphatases is not yet clear. It is known, however, that protein phosphatases play a critical role in ceramide-mediated processes. PKC 14, 16 and Akt 35, 36 are inactivated by PP2A in response to ceramide. In addition, ceramide-mediated activation of PP2A also directly targets PKC and Akt substrates. For instance, ceramide promotes PP2A dephosphorylation of Bcl2 resulting in the loss of Bcl2's anti-apoptotic function. 17 Furthermore, PP2A has recently been shown to directly dephosphorylate Bad. 95 At least for some members of the Bcl2 family, ceramide activation of PP2A promotes anti-survival signaling by targeting Bcl2 family members directly while inactivating their physiologic protein kinases. 17 Ceramide activation of PP1 has not been as well studied as PP2A. Ceramide has been shown to promote dephosphorylation of Rb in association with growth arrest. 96 Recently, phosphatidic acid (PA) has been shown to inhibit PP1 but not PP2A. 97 PA was demonstrated to block ceramide-induced dephosphorylation of Rb and PARP cleavage, thus implicating PP1 in both cell cycle arrest and apoptotic processes, respectively.
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The complexity of ceramide production and topology allow ceramide to participate in diverse signaling pathways Since ceramide can be produced by multiple mechanisms in different subcellular compartments, ceramide has the potential to regulate diverse signal transduction pathways. In addition, since there is a fair level of interaction between the various ceramide metabolic pathways and pathways regulated by effectors that transmodulate ceramide action, downstream effects in response to stress will be complex and varied. In effect, the dominance of a particular pathway (eg ceramidemediated anti-growth signaling vs DAG-mediated pro-growth signaling) in a cell will probably determine the outcome of how that cell responds to the stress challenge. As mentioned above, DAG opposes the effects of ceramide 13 and ceramide can inhibit PKC. [14] [15] [16] Ceramide activation of protein phosphatase results in PKC ␣ dephosphorylation and inactivation. 14, 16 Inactivation of PKC ␣ by TNF-mediated signaling can be blocked by fumonisin B or glutathione and thus suggests a role for both the de novo pathway and neutral SMase pathway in TNF-mediated ceramide production. 16 The complexity of regulation increases as one observes the effects of ceramide on the downstream substrates of PKC ␣. PKC ␣ is a physiologic Bcl2 kinase. 98 Mono-site phosphorylation of Bcl2 at serine 70 is required for Bcl2's full and potent anti-apoptotic function. 99, 100 Bcl2 is dephosphorylated by its physiologic protein phosphatase, PP2A. 101 Ceramide-induced dephosphorylation of Bcl2 via PP2A results in inactivation of Bcl2's anti-apoptotic function. 17 Recent studies focusing on de novo synthesis of ceramide in the mitochondria have found that carnitine palmitoyltransferase I (CPT I) may have a role in ceramide-mediated apoptosis. 102 CPT I facilitates passage of long chain fatty acids to the mitochondria. CPT I expression and ceramide production was elevated in murine LyD9 cells deprived of IL-3 in a fumonisin B-dependent manner. 102 Interestingly, CPT I apparently can bind Bcl2. 103 Perhaps Bcl2 can prevent ceramide synthesis via de novo pathways by sequestering CPT I. The complexity of regulation at the level of just one cellular regulatory molecule becomes clear in the example of ceramide's effects on Bcl2 (Figure 2 ). In this example, how a cell expressing Bcl2 weathers a stress challenge would most probably depend on the mitochondrial levels of PKC ␣, PP2A, CPT I, and other enzymes involved in the de novo ceramide pathway, etc. In addition, the levels of ceramide produced in the mitochondria vs competing levels of antagonistic effectors (eg
Figure 2
Model of how ceramide may regulate apoptosis in the mitochondria. (a) During survival conditions, ceramide production is suppressed in the mitochondria. PKC ␣ and Bcl2 are functional. Bcl2 heterodimerizes with and inactivates Bax. The interaction between CPT I and phosphorylated Bcl2 is speculated. (b) During stress conditions, ceramide is produced in the mitochondria by ceramide synthase. PP2A is activated and inhibits PKC ␣ and Bcl2 function. Bax is free and promotes cytochrome C (cyto C) release from the pore complex prior to cell death. DAG) would influence the function of these proteins at this subcellular location.
It is more than likely that other mechanisms involving regulators of mitochondrial integrity will be affected by alterations in ceramide metabolism. The regulation of apoptosis by signal transduction pathways is complex. 104 Many of the protein kinases and protein phosphatases that participate in these various processes are probably influenced by ceramide, either directly or indirectly. 100 In addition, other signal pathways regulating Bcl2 and other Bcl2 family members are probably regulated by ceramide. For instance, the MAPK extracellular-signal regulated kinases (ERKs) ERK1 and ERK2 phosphorylate Bcl2 at serine 70 under survival conditions. 105 As noted above, ceramide inhibits MAPKs including ERK1 and ERK2. 27 Important upstream regulators of the ERKs including Raf and MEK-1 have been shown to synergize with Bcl2 in blocking cell killing induced by factor withdrawal in both human and murine hematopoietic cell lines. 106, 107 It will be interesting to determine if ceramide affects this synergy. Meanwhile, other important regulatory proteins localized in the membranes of other organelles and in the plasma membrane would undergo similar regulation. Taken as a whole, the capacity of a cell to survive stress stimuli will probably come down to how well the cell's survival signaling pathways can weather a challenge by ceramide.
Ceramide has a novel role in the inhibition of protein synthesis as a prelude to cell death
It is logical that inhibition of protein synthesis may precede apoptosis in cells that are challenged by stress responses. Recently, the inhibition of protein synthesis has been shown to be a prelude to cell death following growth factor withdrawal in IL-3-dependent murine myeloid cells by a mechanism involving the double-stranded RNA-activated protein kinase, PKR. 108 In addition, other stress challenges including treatment with such apoptotic agents as TNF ␣, sodium arsenate, and peroxide were shown to promote PKR activation and inhibit protein synthesis. [109] [110] [111] [112] Since ceramide is suggested as a universal component of apoptosis 1, 6, 10 and PKR is activated during diverse stress stimuli, the question arose whether ceramide may regulate PKR. Indeed, a ceramide-mediated SAPK/JNK pathway regulating apoptosis involving a novel mechanism featuring the inhibition of protein synthesis via the activation of PKR has recently been demonstrated. 89 Activated PKR inhibits protein synthesis by phosphorylating eIF2␣, a molecule required for protein translation initiation events. [113] [114] [115] Until recently, PKR was known only as a component of the host anti-viral defense mechanism where double-stranded viral RNA activated the protein. [113] [114] [115] To account for non-viral activation of PKR in response to stress, a cellular PKR regulator, RAX, was identified. 112 RAX is activated after stress-induced phosphorylation by an as yet unidentified SAPK. 112 Since ceramide is a potent activator of SAPKs, it is not surprising that ceramide was found to promote RAX phosphorylation. 89 In addition, ceramide induces protein synthesis inhibition and is more effective at killing cells that are transfected with RAX as opposed to parental or vector only transfected cells. 89 Thus, JNK or another SAPK could possibly mediate some apoptotic mechanisms by acting through RAX.
Manipulation of ceramide production for chemotherapy in diseases such as leukemia
It is clear that ceramide regulates diverse stress signaling pathways that determine the cell's fate in response to stress stimuli ( Figure 3) . Therefore, defects in ceramide metabolism could potentially affect the cellular response to chemotherapy or other anti-cancer regimens by rendering the cells more resistant to cell killing, and as has been suggested, could contribute to multi-drug resistance.
116 TNF ␣-resistant 117 and adriamycinresistant 75, [118] [119] [120] variants of human cells have been shown to exhibit defects in ceramide metabolism. In the case of adriamycin-resistant cells, ceramide is converted to a non-toxic form (ie glucosylceramide) by glucosylceramide synthase (GCS 73 ). Introduction of GCS into normal MCF-7 cells conferred adriamycin resistance. 118 Conversely, inhibition of GCS in the adriamycin-resistant cells using an oligo-nucleotide anti-sense strategy restored sensitivity to adriamycin. 119 Defects in ceramide metabolism also affect non-chemotherapy anti-cancer strategies. 116 An association between resistance to radiation therapy and defective ceramide metabolism has been shown in Burkitt's lymphoma cells. 120 Thus, dysregulation of ceramide production may be important in chemoresistance.
While defects in ceramide metabolism may be detrimental to patients with diseases such as leukemia, manipulation of ceramide metabolism in patients to promote ceramide production may be of use in remission-induction chemotherapy regimens. Common components of cancer treatment strategy regimens such as chemotherapeutic drug treatment and irradiation promote ceramide production. 18, 19, 24 Could augmentation of ceramide production during chemotherapy potentiate cell killing and lead to more effective anti-cancer strategies? Novel strategies to deliver ceramide directly to malignant cells have yet to be exploited. Currently, strategies being used to target ceramide metabolism focus on GCS activity. 116 The role of aberrant GCS activity to inactivate ceramide toxicity and promote chemoresistance has been demonstrated in a breast cancer cell line. 75, 118, 119 The GCS inhibitor, PPMP (1-phenyl-2-palmitoylamino-3-morpholino-1-propanol),
Figure 3
Ceramide regulates diverse cellular processes. Ceramide regulates diverse stress signaling pathways by affecting transcription (through Jun), translation (through RAX), and the apoptotic machinery (through Bcl2 and Bad). In addition, ceramide promotes inactivation of pro-growth signaling pathways mediated by PKC and Akt.
Leukemia has been shown to augment cell killing of a number of cell lines derived from different solid tumors (eg neuroblastoma, lung adenocarcinoma, breast carcinoma) in combination with the drug, 4-HPR (N-(4-hydroxyphenyl)retinamide). 121 In addition, disruption of ceramide metabolism by the sphingosine analog, safingol, could similarly potentiate cell killing by 4-HPR in these cell lines and in myelogenous and lymphocytic leukemia cell lines. 121 These promising findings suggest that targeting ceramide metabolism may be useful in future novel anti-leukemia strategies.
